By vgreene, 30 October, 2020 Multicenter open label randomized study 130 hospitalized non ICU pts mean 64y w mod severe COVID 19 pneumonia received TCZ 8 mg kg usual care on day 1 and if clinically indicated on day 3 n 64 vs usual care alone n 67 usual care incl abx antivirals CS vas
By vgreene, 30 October, 2020 Study considerations randomized but open label primary outcome amended mid study small sample size usual care not standardized earlier TCZ admin not evaluated CS used more in usual care group
By vgreene, 30 October, 2020 KEY FINDINGS compared w usual care TCZ did not decr dz progression at day 4 or death at day 28 but may reduce risk of ventilation death at day 14
By vgreene, 30 October, 2020 Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID 19 and Moderate or Severe Pneumonia A Randomized Clinical Trial
By vgreene, 29 October, 2020 Consider olanzapine approved only for acute tx resistant MDD when used in combo w fluoxetine1
By vgreene, 29 October, 2020 Offer rTMS but not VNS DBS per VA 1 consider VNS rTMS MST DBS EMDR per ICSI2
By vgreene, 29 October, 2020 Offer MAOI or TCA factoring safety considerations provide pt ed on safety side effects 1 per ICSI use combined psychotherapy pharmaco tx as 1st line if unable to combine these treatments start w pharmaco tx alone 2 avoid MAOIs in pregnancy breastfeeding w
By vgreene, 29 October, 2020 Consider olanzapine approved only for acute tx resistant MDD when used in combo w fluoxetine
By vgreene, 29 October, 2020 Offer rTMS but not VNS DBS per VA 1 consider ketamine infusion VNS rTMs MST DBS EMDR per ICSI3
By vgreene, 29 October, 2020 Offer MAOI or TCA factoring safety considerations 1 provide pt ed on safety side effects per VA 1 per ICSI use combined psychotherapy pharmaco tx as 1st line if unable to combine these txs start w pharmaco tx alone3
